Patents Examined by Marcos L Sznaidman
  • Combinations of cannabinoids and N-acylethanolamines
    Patent number: 11207290
    Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
    Type: Grant
    Filed: August 30, 2019
    Date of Patent: December 28, 2021
    Assignee: SciSparc Ltd.
    Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
  • Use of pridopidine for treating functional decline
    Patent number: 11207310
    Abstract: This invention provides a method of maintaining functional capacity, improving functional capacity, or lessening the decline of functional capacity in a human patient comprising periodically orally administering to the patient a pharmaceutical composition comprising pridopidine such that a dose of 90-225 mg of pridopidine is administered to the patient per day, so as to thereby maintain functional capacity, improve functional capacity, or lessen the decline of functional capacity in the human patient.
    Type: Grant
    Filed: August 24, 2017
    Date of Patent: December 28, 2021
    Assignee: PRILENIA NEUROTHERAPEUTICS LTD.
    Inventors: Michael Hayden, Spyridon Papapetropoulos, Juha-Matti Savola, Eli Eyal, Beth Borowsky, Igor Grachev
  • Agents, compositions and methods for enhancing neurological function
    Patent number: 11207331
    Abstract: Neuro-enhancing agents, compositions and methods are disclosed herein. Preferred neuro-enhancing agents of the present invention include progesterone and metabolites of progesterone, such as 3?-hydroxy-5?-pregnan-20-one (THP). These agents yield neuro-enhancing effects on neural cells that include neural progenitor and/or stem cells, whereby the agents stimulate mitosis of neural progenitor cells, stimulate neurite growth and organization, protect against neural loss, or one or more of these neural processes. Thus, the neuro-enhancing agents, compositions and methods disclosed herein are useful to reverse or prevent neurological disease or defects associated with neural loss or degeneration, such as Alzheimer's disease, neurological injuries, including injuries resulting from radiation therapy, and age-related neurological decline, including impairments in memory and learning.
    Type: Grant
    Filed: May 23, 2017
    Date of Patent: December 28, 2021
    Assignee: UNIVERSITY OF SOUTHERN CALIFORNIA
    Inventors: Roberta Diaz Brinton, Jun Ming Wang
  • Means and methods for treatment of early-onset Parkinson's disease
    Patent number: 11202795
    Abstract: This application relates to the field of neurodegenerative diseases, more particularly to the field of Parkinson's disease. In particular, the disclosure describes that inhibitors reducing FAS activity can be used for treatment of Parkinson's disease, in particular, the treatment of patients suffering from Parkinson's disease having loss of function mutations in PINK1 or PARKIN genes.
    Type: Grant
    Filed: November 20, 2015
    Date of Patent: December 21, 2021
    Assignees: VIB VZW, Katholieke Universiteit Leuven, KU Leuven R&E
    Inventors: Patrik Verstreken, Vanessa Morais Epifânio, Melissa Vos
  • Locally bioavailable drugs
    Patent number: 11202773
    Abstract: Drugs have been designed and developed with a structural motif allowing local bioavailability in the target organ but that are not broadly distributed at a concentration sufficient to illicit toxic side effects in non-targeted organs. The structural motif subjects the compound to be rapidly metabolized by metabolic enzymes before reaching the non-targeted organs.
    Type: Grant
    Filed: April 20, 2016
    Date of Patent: December 21, 2021
    Assignee: University of Houston System
    Inventor: Ming Hu
  • Combinations of cannabinoids and N-acylethanolamines
    Patent number: 11197845
    Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.
    Type: Grant
    Filed: October 10, 2019
    Date of Patent: December 14, 2021
    Assignee: SciSparc Ltd.
    Inventors: Ephraim Brener, Elran Haber, Ascher Shmulewitz
  • Applications for promethazine in preparing anti-liver cancer and/or colon cancer and/or lung cancer products
    Patent number: 11197865
    Abstract: This invention provides uses for promethazine in the preparation of products to treat liver cancer and/or colon cancer and/or lung cancer. From carrying out cancer drug repositioning for the FDA- and CFDA-approved drug promethazine, experiments for this invention show, based on screening of non-anti-cancer drugs for various cancer cell lines (tissue types) and mutation sites, that promethazine has a new use as an anti-liver cancer and/or colon cancer and/or lung cancer medication, thus achieving a new purpose for an old drug.
    Type: Grant
    Filed: June 30, 2015
    Date of Patent: December 14, 2021
    Assignee: SHANGHAI JIAO TONG UNIVERSITY
    Inventors: Yongyong Shi, Zhijian Song
  • Pyrazolyl and pyrimidinyl tricyclic enones as antioxidant inflammation modulators
    Patent number: 11192852
    Abstract: Disclosed herein are novel antioxidant inflammation modulators, including those of the formula: wherein the variables are defined herein. Also provided are pharmaceutical compositions, kits and articles of manufacture comprising such compounds. Methods and intermediates useful for making the compounds, and methods of using the compounds and compositions thereof are also provided.
    Type: Grant
    Filed: December 3, 2019
    Date of Patent: December 7, 2021
    Assignee: REATA PHARMACEUTICALS, INC.
    Inventors: Eric Anderson, Gary L. Bolton, Bradley Caprathe, Xin Jiang, Chitase Lee, William H. Roark, Melean Visnick
  • Amino pyrimidine derivatives
    Patent number: 11180460
    Abstract: The present invention describes new amino pyrimidine derivatives and pharmaceutically acceptable salts thereof which appear to interact with Bruton's tyrosine kinase (Btk). Accordingly, the novel amino pyrimidines may be effective in the treatment of autoimmune disorders, inflammatory diseases, allergic diseases, airway diseases, such as asthma and chronic obstructive pulmonary disease (COPD), transplant rejection, cancers e.g. of hematopoietic origin or solid tumors.
    Type: Grant
    Filed: September 16, 2019
    Date of Patent: November 23, 2021
    Assignee: Novartis AG
    Inventors: Daniela Angst, Francois Gessier, Anna Vulpetti
  • Essential oil of with a high geraniol content, and use for treating greasy skin and/or the associated aesthetic defects
    Patent number: 11179316
    Abstract: The present invention relates to an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, in particular of Satureja montana L. ssp. variegata. The present invention also relates to the cosmetic use of an essential oil of Satureja montana comprising more than 60% by weight of geraniol and more than 5% by weight of trans-?-caryophyllene, in particular of Satureja montana L. ssp. variegata, for treating greasy skin and/or preventing greasy or greasy-prone skin and/or the associated aesthetic skin defects. The invention also relates to a cosmetic composition comprising said oil, to a non-therapeutic cosmetic care and/or cleansing treatment process for greasy skin, and also to said essential oil as a dermatological agent.
    Type: Grant
    Filed: April 18, 2014
    Date of Patent: November 23, 2021
    Assignee: L'OREAL
    Inventors: Géraldine Lerebour, Pierre Lartaud, Bertrand Lacroix
  • Dermatophytosis prophylaxis and treatment
    Patent number: 11154527
    Abstract: A composition and method for the prophylaxis and treatment of topical fungal infections is provided. Generally, the composition includes an HMG-CoA reductase inhibitor and a carrier. In some forms, the composition further includes an anti-fungal agent. The method generally includes the steps of applying the composition topically once or multiple times. The composition and method can be used in combination with another form of fungal treatment, such as oral medications.
    Type: Grant
    Filed: August 26, 2019
    Date of Patent: October 26, 2021
    Assignee: The Children's Mercy Hospital
    Inventors: Susan Abdel-Rahman, Barry L. Preuett, J. Steven Leeder
  • Dual active parasiticidal granule compositions, methods and uses thereof
    Patent number: 11147273
    Abstract: The present invention encompasses a stabilized parasiticidal granule composition comprising a macrocyclic lactone compound and an insect growth regulator. The invention also encompasses methods of making and methods of using the granule for treating, controlling or preventing parasitic infestation or parasitic infection in an animal.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: October 19, 2021
    Assignee: BOEHRINGER INGELHEIM ANIMAL HEALTH USA INC.
    Inventors: Kour Chand Jindal, Jian Han, Kim Agnew
  • Methods for the diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions in canines
    Patent number: 11143660
    Abstract: The invention relates to methods of diagnosis, control and prophylaxis of inflammation and mitigation of inflammatory conditions, particularly arthritis and joint pain, in canines, comprising measuring inflammatory biomarkers wherein elevated levels of the biomarkers in blood correlates to reduced inflammation and reduced levels in blood correlates to increase level in the tissues. The invention further provides a method to treat or control inflammation comprising administering a diet comprising increased levels of one or more of DHA, EPA, vitamin C, vitamin E, and/or L-carnitine.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: October 12, 2021
    Assignee: Hills Pet Nutrition, Inc.
    Inventor: Nolan Frantz
  • Opioid ketal compounds and uses thereof
    Patent number: 11130765
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently H or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: April 28, 2020
    Date of Patent: September 28, 2021
    Assignee: Rhodes Technologies
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Metal delivery agents and therapeutic uses of the same
    Patent number: 11123350
    Abstract: The present invention relates to metal complexes, processes for their preparation and their use as pharmaceutical or veterinary agents, in particular for the treatment of conditions in which metal delivery can prevent, alleviate or ameliorate the condition. There are a number of clinical conditions which are caused by or associated with abnormal levels of metals (typically low metal levels). Conditions in of this type include cancer and conditions characterised by or associated with oxidative damage, more specifically neurodegenerative conditions such as Alzheimer's disease, Parkinson's disease or Huntington's disease. The invention also relates to ligands useful in the preparation of metal complexes of this type.
    Type: Grant
    Filed: June 6, 2019
    Date of Patent: September 21, 2021
    Assignee: The University of Melbourne
    Inventors: Paul Donnelly, James Hilton, Peter Crouch
  • Glutamine antagonists for the treatment of cognitive deficits and psychiatric disorders
    Patent number: 11110104
    Abstract: The disclosure provides compounds having formula (I): and the pharmaceutically acceptable salts thereof, wherein R1, R2, R2?, and X are as defined as set forth in the specification, for use in treating cognitive deficits and/or psychiatric disorders, such as those associated with neurological or neurodegenerative disorders, psychiatric or mood disorders, and HIV-associated neurocognitive disorders (HAND). Compounds having formula (I) are prodrugs that release glutamine analogs, e.g., 6-diazo-5-oxo-L-norleucine (DON).
    Type: Grant
    Filed: January 31, 2018
    Date of Patent: September 7, 2021
    Assignees: The Johns Hopkins University, Icahn School of Medicine at Mount Sinai
    Inventors: Barbara Slusher, David Volsky, Mike Nedelcovych, Kristen Hollinger, Atsushi Kamiya
  • Clonidine and/or clonidine derivatives for use in the prevention of skin injury resulting from radiotherapy
    Patent number: 11090290
    Abstract: The present invention pertains to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and Clonidine and/or Clonidine derivatives as a sole active ingredient for use in the prevention of skin injury resulting from radiotherapy by transmucocal administration.
    Type: Grant
    Filed: May 10, 2016
    Date of Patent: August 17, 2021
    Assignee: MONOPAR THERAPEUTICS, INC.
    Inventors: Bérangère Vasseur-Demarcy, Pierre Attali
  • Opioid ketal compounds and uses thereof
    Patent number: 11091496
    Abstract: This invention relates to opioid ketal compounds of Formula (I), Formula (II), or Formula (III): or a pharmaceutically acceptable salts thereof, wherein R1 is H or CH3, R2 is H or OH, n is 0, 1, 2 or 3, R3 and R4 are independently or optionally substituted C1-C4 alkyl, or when n is 0, then R3 and R4 and the carbon atoms to which they are attached together form six, or seven membered ring, which is optionally mono or disubstituted by C1-C4 alkyl. The invention also relates to oxycodone ketal compounds of Formula (IV) or (V): or a pharmaceutically acceptable salts thereof. The invention also relates to the use of such compounds for the treatment, prevention, or amelioration of pain.
    Type: Grant
    Filed: July 22, 2019
    Date of Patent: August 17, 2021
    Assignee: RHODES TECHNOLOGIES
    Inventors: Robert J. Kupper, Raymond C. Glowaky
  • Compositions comprising triterpenoids
    Patent number: 11083736
    Abstract: The invention relates to compositions and formulations comprising at least one triterpenoic acid and at least one neutral triterpenoid and uses thereof for treating stroke or trauma and side effects related thereto.
    Type: Grant
    Filed: June 25, 2019
    Date of Patent: August 10, 2021
    Assignee: REGENERA PHARMA LTD.
    Inventors: Zadik Hazan, Konstantin Adamsky, Andre C. B. Lucassen, Nurit Novak
  • Dermatomycosis treatment agent
    Patent number: 11083701
    Abstract: Provided is a means effective in treating dermatomycosis. An external therapeutic agent for treating dermatomycosis containing a trialkali metal salt of citric acid.
    Type: Grant
    Filed: June 20, 2016
    Date of Patent: August 10, 2021
    Inventor: Shiro Yoshizaki